Mereo BioPharma Group plc Stock Analysis & AI Score
Mereo BioPharma Group plc (MREO) has an ST Score of 47.1 (C+), driven by its Momentum (B+) and held back by its Profitability (D-). Analysts rate it Buy with a $3.25 price target (+863.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Mereo BioPharma Group plc (MREO) has an ST Score of 47.1 (C+), driven by its Momentum (B+) and held back by its Profitability (D-). Analysts rate it Buy with a $3.25 price target (+863.0% upside).
- Strongest
- MomentumB+
- Weakest
- ProfitabilityD-
All factor grades
- MomentumB+
- ForecastB+
- ValuationB
- GrowthB
- Financial StrengthC
- ProfitabilityD-
- Piotroski1/9
Contact
MREO stock: frequently asked questions
What is MREO's ST Score?
Mereo BioPharma Group plc (MREO) has an ST Score of 47.1 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MREO a buy, hold, or sell?
Analysts rate MREO a Buy, with a price target of $3.25 (+863.0% vs the current price). Our ST Score grades it C+ (47.1/100). The ST Score is a data-driven signal, not a recommendation.
What are MREO's factor grades?
Valuation B, Profitability D-, Financial Strength C, Momentum B+, Growth B, Forecast B+.
What is MREO's valuation grade?
Mereo BioPharma Group plc (MREO) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MREO's growth grade?
Mereo BioPharma Group plc (MREO) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MREO's profitability grade?
Mereo BioPharma Group plc (MREO) earns a profitability grade of D-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MREO's financial strength grade?
Mereo BioPharma Group plc (MREO) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MREO?
The average analyst price target for Mereo BioPharma Group plc (MREO) is $3.25 from 8 analysts, which is +863.0% versus the recent price of $0.34.
What is MREO's Piotroski score?
Mereo BioPharma Group plc (MREO) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.